Business context and reporting period
Pro-Dex, Inc. designs and manufactures powered surgical drivers and shavers, primarily for orthopedic, thoracic and craniomaxillofacial markets, and also sells rotary air motors. The filing is a Form 10-K for the fiscal year ended June 30, 2021; this differs from the request metadata’s “2020 Q4.”
Medical devices provided 85% of fiscal 2021 sales; repairs contributed 13%. The company reported one operating segment.
Financial performance and position
| Metric | FY2021 | FY2020 |
|---|---|---|
| Net sales | $38.0 million | $34.8 million |
| Gross profit / margin | $13.6 million / 36% | $13.1 million / 38% |
| Operating income | $4.5 million | $7.1 million |
| Net income | $4.5 million | $6.1 million |
| Diluted EPS | $1.13 | $1.50 |
| Operating cash flow | $(2.1) million | $4.9 million |
Sales grew 9%, while net income fell 27%. Gross margin declined two percentage points as cost of sales rose 13%. Operating expenses increased 49% to $9.1 million, led by higher R&D ($4.4 million versus $2.3 million) and general and administrative expense. FY2021 net income included a $1.3 million gain on investment sales; FY2020 included $952,000 of other income from repayment of a note receivable.
At June 30, 2021, cash and cash equivalents were $3.7 million (versus $6.4 million); working capital was $19.1 million (versus $17.4 million). Total assets were $40.3 million and total liabilities $20.2 million. Notes payable totaled approximately $12.8 million, compared with $3.9 million a year earlier. The company also held $3.0 million of marketable equity securities, including thinly traded holdings.
Operating cash use primarily reflected a $5.8 million increase in accounts receivable after the largest customer’s payment terms changed from net 30 to net 90. Investing cash use was $3.7 million, including the Tustin property purchase and capital expenditures. Financing cash provided $3.1 million, including bank borrowings, partly offset by $5.5 million in share repurchases. The $2.0 million revolving credit facility was undrawn at year-end.
Material changes versus the prior year
- Medical-device revenue increased $5.5 million, mainly on thoracic driver sales to the second-largest customer; its sales rose to $10.1 million from $5.9 million.
- Repair revenue declined $1.4 million to $5.0 million; management expects further declines in repairs of a major orthopedic handpiece.
- R&D spending rose $2.1 million, reflecting increased engineering consultants and internal development programs. Management expects R&D to increase as product development continues.
- The company acquired a 25,000-square-foot Tustin facility for $6.5 million, financed partly with a property loan, and continued its build-out.
- Share repurchases reduced shares outstanding: 216,171 shares were repurchased for $5.5 million in FY2021.
Outlook, risks and unusual items
Management expected the Tustin facility to begin operations in the first quarter of fiscal 2022, expanding battery and new-product capacity. It stated that cash, receivables and expected operating cash flows should cover requirements for at least 12 months, while noting possible future needs for debt or equity funding. The $9.7 million year-end backlog was expected to be delivered in fiscal 2022 in the MD&A; another passage in the filing gives a conflicting fiscal-year delivery reference, which investors should verify.
Customer concentration is a key risk: the top three customers generated 91% of FY2021 sales, with the largest at 58%. That customer’s supply agreement was extended through calendar 2025. COVID-19 had not materially affected FY2021 results, but customer shipment delays, supplier lead times and possible elective-surgery disruptions remained risks. Other disclosed risks include order cancellations, competition, product acceptance and warranty costs, supplier dependencies, regulatory compliance, cybersecurity, and debt covenants.
On August 24, 2021, a customer sought indemnification related to a third-party patent-infringement complaint involving a product Pro-Dex manufactures for that customer. The company had not accrued a loss and had not completed its assessment as of the filing. The auditor gave an unqualified opinion on the financial statements and identified valuation of thinly traded investments as a critical audit matter. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not attest to internal controls.
Important facts for investors to verify
- Confirm the reporting-period mismatch in the request metadata and the backlog delivery-year inconsistency in the filing text.
- Track collections under the largest customer’s net-90 payment terms and the resulting working-capital and operating-cash-flow effects.
- Assess customer concentration, the durability of the thoracic driver sales ramp, and the expected decline in repair revenue.
- Monitor Tustin facility completion, start-up timing, related capital costs, and whether added capacity generates profitable sales.
- Review total debt, scheduled repayments, revolver renewal and covenant compliance, alongside management’s 12-month liquidity assessment.
- Follow developments in the patent-indemnification matter and the valuation and liquidity of the company’s thinly traded investments.